[go: up one dir, main page]

WO1991009593A3 - Antagonistes 5-ht3 de traitement de la nausee de la bradycardie de l'hypotension associee a une instabilite du myocarde - Google Patents

Antagonistes 5-ht3 de traitement de la nausee de la bradycardie de l'hypotension associee a une instabilite du myocarde Download PDF

Info

Publication number
WO1991009593A3
WO1991009593A3 PCT/GB1990/001996 GB9001996W WO9109593A3 WO 1991009593 A3 WO1991009593 A3 WO 1991009593A3 GB 9001996 W GB9001996 W GB 9001996W WO 9109593 A3 WO9109593 A3 WO 9109593A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bradycardia
nausea
antagonists
hypotension associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1990/001996
Other languages
English (en)
Other versions
WO1991009593A2 (fr
Inventor
Edward Stewart Johnson
Thomas Conway Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Priority to KR1019920701481A priority Critical patent/KR920703037A/ko
Publication of WO1991009593A2 publication Critical patent/WO1991009593A2/fr
Publication of WO1991009593A3 publication Critical patent/WO1991009593A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Méthode de traitement et ou de prophylaxie de la nausée et de la bradycardie et/ou de l'hypotension associées à une instabilité myocardique chez les mammifères, par exemple chez l'homme. Cette méthode prévoit d'administrer aux mammifères nécessitant ce traitement et/ou cette prophylaxie une quantité efficace et/ou prophylactique d'un antagoniste du récepteur 5-HT3, par exemple un composé de formule (I): X-A-R, ou un sel de celui-ci pharmaceutiquement acceptable, où X est un groupe phényle ou un groupe hétéroaryle monocyclique à 5 ou 6 éléments. Dans un cas comme dans l'autre, chaque groupe est fusionné à un noyau carbocyclique ou hétérocyclique saturé on insaturé à 5-7 éléments; A est une partie de liaison; et R est une partie azabicyclique saturée ou une partie imidazolyle.
PCT/GB1990/001996 1989-12-21 1990-12-20 Antagonistes 5-ht3 de traitement de la nausee de la bradycardie de l'hypotension associee a une instabilite du myocarde Ceased WO1991009593A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019920701481A KR920703037A (ko) 1989-12-21 1990-12-20 심근 불안정과 관련된 저혈압증, 구기, 서맥의 치료를 위한 5-ht₃길항질

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898928837A GB8928837D0 (en) 1989-12-21 1989-12-21 Pharmaceuticals
GB8928837.7 1989-12-21

Publications (2)

Publication Number Publication Date
WO1991009593A2 WO1991009593A2 (fr) 1991-07-11
WO1991009593A3 true WO1991009593A3 (fr) 1991-09-05

Family

ID=10668280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1990/001996 Ceased WO1991009593A2 (fr) 1989-12-21 1990-12-20 Antagonistes 5-ht3 de traitement de la nausee de la bradycardie de l'hypotension associee a une instabilite du myocarde

Country Status (9)

Country Link
EP (1) EP0506813A1 (fr)
JP (1) JPH05502872A (fr)
KR (1) KR920703037A (fr)
AU (1) AU7051691A (fr)
CA (1) CA2071994A1 (fr)
GB (1) GB8928837D0 (fr)
IE (1) IE904603A1 (fr)
WO (1) WO1991009593A2 (fr)
ZA (1) ZA9010219B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576094B2 (en) 2004-12-13 2009-08-18 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AP1635A (en) 2001-10-02 2006-07-14 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
MXPA04004373A (es) 2001-11-09 2004-08-11 Upjohn Co Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0307714A (pt) 2002-02-15 2005-02-09 Upjohn Co Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns
EP1476448A2 (fr) 2002-02-19 2004-11-17 PHARMACIA & UPJOHN COMPANY Composes azabicycliques servant a traiter des maladies
AU2003219690A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
EP1697378B1 (fr) 2003-12-22 2007-11-21 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation
EP1735306A2 (fr) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
EP1742944B1 (fr) 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, leur preparation et leurs utilisations
KR20070015607A (ko) 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
ATE455776T1 (de) 2004-12-22 2010-02-15 Memory Pharm Corp Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125398A (en) * 1982-06-29 1984-03-07 Sandoz Ltd Bridged piperidyl esters and amides
GB2152049A (en) * 1983-12-23 1985-07-31 Sandoz Ltd Benzoic acid derivative
GB2153821A (en) * 1984-01-25 1985-08-29 Glaxo Group Ltd 3-Imidazolylmethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one derivatives
EP0191562A2 (fr) * 1985-01-23 1986-08-20 Glaxo Group Limited Dérivés de tétrahydrocarbazolones
EP0200444A2 (fr) * 1985-04-27 1986-11-05 Beecham Group Plc Azabicyclononyl-indazole carboxamide ayant une activité antagoniste de la 5-HT
EP0210840A2 (fr) * 1985-07-24 1987-02-04 Glaxo Group Limited Imidazolylméthyltétrahydrocarbazolones substituées
EP0219193A1 (fr) * 1985-07-24 1987-04-22 Glaxo Group Limited Dérivés de tétrahydrocarbazolone, procédés pour leur préparation et compositions pharmaceutiques les contenant
EP0247266A1 (fr) * 1986-01-07 1987-12-02 Beecham Group Plc Dérivés d'indole ayant une chaîne latérale azabicyclique, procédé pour leur préparation, produits intermédiaires et compositions pharmaceutiques
EP0266730A1 (fr) * 1986-11-03 1988-05-11 Merrell Dow Pharmaceuticals Inc. Esters de l'hexahydro-8-hydroxy-2,6-méthano-2H-quinolizin-3-(4H)-one et composés apparentés
EP0269452A2 (fr) * 1986-11-28 1988-06-01 Glaxo Group Limited Application de dérivés de cétone pour la fabrication de médicaments
EP0276163A2 (fr) * 1987-01-23 1988-07-27 Glaxo Group Limited Dérivés d'indole
EP0294292A2 (fr) * 1987-06-04 1988-12-07 Adir Et Compagnie Dérivé de l'acide benzo [B] thiophène - 7 carboxylique, son procédé de préparation et les compositions pharmaceutiques qui le contiennent
EP0306323A2 (fr) * 1987-09-03 1989-03-08 Glaxo Group Limited Dérivés de lactames
EP0315390A2 (fr) * 1987-11-04 1989-05-10 Beecham Group Plc Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline
EP0315316A2 (fr) * 1987-10-02 1989-05-10 Beecham Group Plc Dérivés d'imidazole, procédé pour leur préparation, compositions pharmaceutiques les contenant, et leur application pharmaceutique
DE3740984A1 (de) * 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
EP0322016A1 (fr) * 1987-12-10 1989-06-28 Duphar International Research B.V Acides, esters et amides d'indoles, 1,7-annelés, carboxyliques
EP0336759A1 (fr) * 1988-04-07 1989-10-11 Glaxo Group Limited Dérivés d'imidazole
DE3810552A1 (de) * 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0350129A1 (fr) * 1988-07-07 1990-01-10 Duphar International Research B.V Indole cétones annelées avec un substituant imidazolylalkyle
EP0351385A2 (fr) * 1988-07-12 1990-01-17 BOEHRINGER INGELHEIM ITALIA S.p.A. Dérivés d'amidino et de guanidino
EP0373061A1 (fr) * 1988-12-06 1990-06-13 Adir Et Compagnie Nouveaux dérivés de l'indole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0376624A1 (fr) * 1988-12-22 1990-07-04 Yamanouchi Pharmaceutical Co. Ltd. Dérivés de 4,5,6,7-tétrahydrobenzimidazole et leur préparation
EP0378111A1 (fr) * 1989-01-09 1990-07-18 ZAMBON GROUP S.p.A. Dérivés d'isoxazole doués d'activité antisérotonine, procédé pour leur préparation et compositions les contenant

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125398A (en) * 1982-06-29 1984-03-07 Sandoz Ltd Bridged piperidyl esters and amides
GB2152049A (en) * 1983-12-23 1985-07-31 Sandoz Ltd Benzoic acid derivative
GB2153821A (en) * 1984-01-25 1985-08-29 Glaxo Group Ltd 3-Imidazolylmethyl-1,2,3,9-tetrahydro-4H-carbazol-4-one derivatives
EP0191562A2 (fr) * 1985-01-23 1986-08-20 Glaxo Group Limited Dérivés de tétrahydrocarbazolones
EP0200444A2 (fr) * 1985-04-27 1986-11-05 Beecham Group Plc Azabicyclononyl-indazole carboxamide ayant une activité antagoniste de la 5-HT
EP0210840A2 (fr) * 1985-07-24 1987-02-04 Glaxo Group Limited Imidazolylméthyltétrahydrocarbazolones substituées
EP0219193A1 (fr) * 1985-07-24 1987-04-22 Glaxo Group Limited Dérivés de tétrahydrocarbazolone, procédés pour leur préparation et compositions pharmaceutiques les contenant
EP0247266A1 (fr) * 1986-01-07 1987-12-02 Beecham Group Plc Dérivés d'indole ayant une chaîne latérale azabicyclique, procédé pour leur préparation, produits intermédiaires et compositions pharmaceutiques
EP0266730A1 (fr) * 1986-11-03 1988-05-11 Merrell Dow Pharmaceuticals Inc. Esters de l'hexahydro-8-hydroxy-2,6-méthano-2H-quinolizin-3-(4H)-one et composés apparentés
EP0269452A2 (fr) * 1986-11-28 1988-06-01 Glaxo Group Limited Application de dérivés de cétone pour la fabrication de médicaments
EP0276163A2 (fr) * 1987-01-23 1988-07-27 Glaxo Group Limited Dérivés d'indole
EP0294292A2 (fr) * 1987-06-04 1988-12-07 Adir Et Compagnie Dérivé de l'acide benzo [B] thiophène - 7 carboxylique, son procédé de préparation et les compositions pharmaceutiques qui le contiennent
EP0306323A2 (fr) * 1987-09-03 1989-03-08 Glaxo Group Limited Dérivés de lactames
EP0315316A2 (fr) * 1987-10-02 1989-05-10 Beecham Group Plc Dérivés d'imidazole, procédé pour leur préparation, compositions pharmaceutiques les contenant, et leur application pharmaceutique
EP0315390A2 (fr) * 1987-11-04 1989-05-10 Beecham Group Plc Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline
DE3740984A1 (de) * 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
EP0322016A1 (fr) * 1987-12-10 1989-06-28 Duphar International Research B.V Acides, esters et amides d'indoles, 1,7-annelés, carboxyliques
DE3810552A1 (de) * 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0336759A1 (fr) * 1988-04-07 1989-10-11 Glaxo Group Limited Dérivés d'imidazole
EP0350129A1 (fr) * 1988-07-07 1990-01-10 Duphar International Research B.V Indole cétones annelées avec un substituant imidazolylalkyle
EP0351385A2 (fr) * 1988-07-12 1990-01-17 BOEHRINGER INGELHEIM ITALIA S.p.A. Dérivés d'amidino et de guanidino
EP0373061A1 (fr) * 1988-12-06 1990-06-13 Adir Et Compagnie Nouveaux dérivés de l'indole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0376624A1 (fr) * 1988-12-22 1990-07-04 Yamanouchi Pharmaceutical Co. Ltd. Dérivés de 4,5,6,7-tétrahydrobenzimidazole et leur préparation
EP0378111A1 (fr) * 1989-01-09 1990-07-18 ZAMBON GROUP S.p.A. Dérivés d'isoxazole doués d'activité antisérotonine, procédé pour leur préparation et compositions les contenant

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Baillieres Clin. Gastroenterol., vol. 2, Nr. 1, January 1988 P.L.R. Andrews: "The neurophysiology ofvomiting", pages 141-168 *
Br. J. Pharmacol., vol. 94, Nr. 2, June 1988, The Macmillan Press Ltd A. Butler et al.: "Pharmacological prperties of GR38032F, a novel antagonist at 5-HT3 receptors", pages 397-412 *
Clinical and Experimental Pharmacology and Physiology, vol. 17, Nr. 9, September 1990 (Australia) R.G. Eans et al.: "Characteristics of cardiovascular reflexes originating from 5-HT3 receptors in the heart and lungs of unanaesthetized rabbits", pages 665-679 *
J. Auton. Pharmacol., vol. 6, Nr. 3, September 1986, D.W. Dalton et al.: "An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and doca salt hypertensive rats", pages 219-228 *
J. Mol. Cell Cardiol., vol. 21, Suppl. 2, 1989, Congress Ann Arbor, Michigan, 14-18 May 1989 H. Kameda et al.: "The effects of ICS 205-930. A new 5-HT3 receptor antagonist on responses of guinea pig atria page S188 *
J. Mol. Cell Cardiol., vol. 21, Suppl. 2, 1989; Congress Ann Arbor, Michigan, 14-18 May 1989; H. Kameda et al.: "Cardiac effect of novel serotonin receptor (5-HT3) antagonists in guinea pigs", page S115, *
J. Pharm. Pharmacol., vol. 40, Nr. 8, August 1988 N.M. Barnes et al.: "Identification of 5-HT3 recognition sites in the ferret area postrema", pages 586-588 *
Journal of Cardiovascular Pharmacology, vol. 13, Nr. 4, April 1989, Raven Press Ltd (New York, US) C. E. Wright et al.: "5-Carboxamido-tryptamine elicites 5-HT2 and 5-HT3 receptor-mediated cardiovascular responses in the conscious rabbit: evidence for 5-ht release from platelets" pages 557-564 *
Naunyn Schimedeberg's Archives of Pharmacology , vol. 335, Nr. 6, June 1987, Springer Verlag G. Scholtysik: "Evidence for inhibition by ICS 205-930 and stimulation by BRL 34915 of K+ conductance in cardiac muscle", pages 692-696 *
Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 339, Nr. 3, March 1989, Springer Verlag H. Bertold et al.: "Inhibition of the 5-HT-induced cardiogenic hypertensive chemsreflex by the selective 5-HT3 receptor antagonist ICS 205-930" pages 259-262 *
The Journal of Pharmacology and Experimental Therapeutics, vol. 252, no. 2, February 1990 (US) H. WIlson et al.: "5-Hydroxytrptamine3 receptors mediate tachycardia in conscious instrumented dogs", pages 683-688 *
The Journal of Pharmacology and Experimental Therapeutics, vol. 254, no. 1, July 1990 (US) M.L. Cohen et al.: "LY277359 Maleate: a potent and selecti e 5-HT3 receptor antagonist without gastropokineic activity", pages 350-355 *
The Journal of Pharmacology and Experimentsl Therapeutics, vol. 248, Nr. 1, January 1989 (US) M.L. Cohen et al.: Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride", pages 197-201 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576094B2 (en) 2004-12-13 2009-08-18 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9273044B2 (en) 2010-05-17 2016-03-01 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9550767B2 (en) 2010-05-17 2017-01-24 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Also Published As

Publication number Publication date
AU7051691A (en) 1991-07-24
CA2071994A1 (fr) 1991-06-22
IE904603A1 (en) 1991-07-03
ZA9010219B (en) 1991-11-27
WO1991009593A2 (fr) 1991-07-11
KR920703037A (ko) 1992-12-17
JPH05502872A (ja) 1993-05-20
GB8928837D0 (en) 1990-02-28
EP0506813A1 (fr) 1992-10-07

Similar Documents

Publication Publication Date Title
WO1991009593A3 (fr) Antagonistes 5-ht3 de traitement de la nausee de la bradycardie de l'hypotension associee a une instabilite du myocarde
NO175309C (no) Analogifremgangsmåte for fremstilling av nye, terapeutisk virksomme tricykliske, nitrogenholdige forbindelser
HUT62892A (en) Process for producing iso-and heterocyclic compounds furnished with imidazole ring and pharmaceutical compositions comprising same as active ingredient
RU95101430A (ru) Производные 1-бифенилметилимидазола, их получение, фармацевтическая композиция, способ лечения или профилактики гипертонии
KR920008006A (ko) 류코트리엔 길항제로서의 불포화 하이드록시 알킬퀴놀린산
MY131501A (en) Process for the prepration of clavulanic acid
ES2057016T3 (es) Compuestos de acido 3-pirrolidiniltio-1-azabiciclo (3.2.0) hept-2-eno-2-carboxilico.
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
FI98368B (fi) Menetelmä valmistaa farmaseuttisesti vaikuttavaa 3-(bifenyl-4-yyli)metyyli-4,5,6,7-tetrahydroimidatso[4,5-c]pyridiinijohdannaista
KR930702345A (ko) 3,9-다아자비시클로(3,3,1) 노난-7-일 유도체, 이들의 제조를 위한 방법 및 중간체 및 이들을 함유한 제약학적 조성물
FI882909A0 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten furanyylimetyylisubstituoitujen bentsimidatsoli- ja imidatsopyridiinijohdannaisten valmistamiseksi
UA37311C2 (uk) Засіб для лікування статевої дисфункції і фармацевтичний препарат
DE60016786D1 (de) Bicyclische vasopressin-agoniste
ES8501390A1 (es) Procedimiento para la preparacion de nuevas dibenzodiazepinonas sustituidas
PT87025A (pt) Process for the preparation of imidazol derivatives and of pharmaceutical compositions containing the same
GB902659A (en) A process for the production of a derivative of thebaine
KR880005134A (ko) 인돌로-피라지노-벤조 디아제민 유도체
ZA894098B (en) Alpha-adrenergic receptor antagonists
YU11494A (sh) Postupak za dobijanje derivata piperazinilkamforsulfonila kao antagonista oksitocina
EP0370712A3 (fr) Dérivés de l'éthylamine et médicaments hypotenseurs les contenant
KR840008650A (ko) 폴리사이클릭 카복실산 화합물의 제조방법
EP0403882A3 (fr) Dérivés d'indole et procédé pour leur préparation
EP0116255A3 (fr) Dérivés de N-alkyl-pipéridinyl benzoates, agents anti-migraine
EP0344982A3 (fr) Antagonistes des récepteurs alpha-adrénergiques
ZA894099B (en) Alpha-adrenergic receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991901843

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2071994

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991901843

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991901843

Country of ref document: EP